Item 8.01. Other Events.
On July 11, 2019, Ritter Pharmaceuticals, Inc. (the "Company") issued a press
release announcing that it had received written notice from Nasdaq that the
Company's minimum bid price deficiency has been cured and that the Company is in
compliance with all applicable listing standards. A copy of the press release is
attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press Release dated July 11, 2019, entitled "Ritter Pharmaceuticals
Regains Compliance with Nasdaq's Minimum Bid Price Requirement -
Ritter Shares Will Continue to Trade on the Nasdaq Capital Market"
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
RITTER PHARMACEUTICALS, INC.
By: /s/ Andrew J. RitterName: Andrew J. Ritter
Title: Chief Executive Officer
Date: July 11, 2019
© Edgar Online, source Glimpses